Latest News and Press Releases

BASEL, Switzerland, Jan. 20, 2005 (PRIMEZONE) --Novartis (NYSE:NVS): * 75 projects in development, including 43 new molecular entities * Key late-stage projects progressing on track * New data...

BASEL, Switzerland, Dec. 1, 2004 (PRIMEZONE) -- First-in-class approval solidifies already established cardio-protective benefits of leading high blood pressure agent Paves the way for further...

BASEL, Switzerland, Nov. 30, 2004 (PRIMEZONE) -- Novartis Pharma AG announced today that it has withdrawn the application for the EU Mutual Recognition Procedure for Prexige(R) (lumiracoxib) to await...

BASEL, Switzerland, March 12, 2004 (PRIMEZONE) -- Responding to a request by AMF, the French market authority, Novartis AG confirms they are exploring the feasibility of a combination with Aventis....

BASEL, Switzerland, Feb. 10, 2004 (PRIMEZONE) -- Novartis Pharma AG (NYSE:NVS) announced today that its application for the new enteric-coated immunosuppressant, Myfortic (mycophenolate sodium)...

BASEL, Switzerland, Jan. 30, 2004 (PRIMEZONE) -- Novartis Pharma AG announced it has filed an application to various regulatory authorities for a new indication for Diovana (valsartan) to improve...

BASEL, Switzerland, Jan. 22, 2004 (PRIMEZONE) -- Novartis posts leading growth among top-ten pharmaceutical companies(1), sustaining double-digit increase in sales and operating income in...

BASEL, Switzerland, Jan. 20, 2004 (PRIMEZONE) -- Please note that Novartis will publish its financial results for 2003 on Thursday, January 22, 2004 at approximately 7.15 a.m. (Swiss time) through...

BASEL, Switzerland, Dec. 16, 2003 (PRIMEZONE) -- Novartis: -- Transaction offers Novartis entry to U.S. retail medical nutrition channel and enhanced access to Japanese market --...

BASEL, Switzerland, and NEW YORK, Nov. 19, 2003 (PRIMEZONE) -- Novartis: New positive Phase II data on LAF237 (type-II diabetes), SPP100 (hypertension), AAE581 (osteoporosis) and QAB149 (asthma...